BUSINESS

• Shionogi Ups Earnings Outlook on Xofluza Boost
  July 24, 2018

• Daiichi Sankyo’s Herceptin Biosimilar Might Hit Market as Early as November, Breast Cancer Use Also Eyed
  July 23, 2018

• Maruho to Increase Information Supply to Non-Dermatologists Using Digital Technology
  July 23, 2018

• Wakamoto to Initiate PIII Study of Treatment for Ocular Hypertension
  July 23, 2018

• J-TEC Submits Trial Protocol for Autologous Cultured Cartilage in Knee Osteoarthritis Use
  July 20, 2018

• Toray, Bonac to Begin US PI Trial of Nucleic Acid for IPF
  July 20, 2018

• Subcutaneous Vedolizumab Hits Primary Endpoint in PIII: Takeda
  July 20, 2018

• Takeda, Ovid Launching 3 New Studies for Rare Epilepsy Drug
  July 20, 2018

• Steep Hikes in Prices of Chinese-Made APIs Could Hit Generic Makers Hard
  July 20, 2018

• Fuji Pharma Poised to Develop New Biosimilar in Women’s Health/Acute Care
  July 19, 2018

• Belviq Didn’t Increase CV Events in Outcome Study: Eisai
  July 19, 2018

• Entyvio Filed for Crohn’s Disease in Japan: Takeda
  July 19, 2018

• Teva Takeda to Wind Up Sale of 48 Products towards Stable Supply
  July 18, 2018

• Xofluza Hits Primary Endpoint in High Risk Flu Patients: Shionogi
  July 18, 2018

• Chugai to Develop ROS1/TRK Inhibitor Entrectinib in Japan
  July 18, 2018

• AZ Initiates PIII Study of Nexium for Pediatric Indications at Request of AMED, Pediatric Society
  July 18, 2018

• FDA OKs Xtandi for Non-Metastatic Prostate Cancer
  July 18, 2018

• Epadel to Enter Clinical Study in China: Mochida, Sumitomo Dainippon
  July 18, 2018

• Lilly Japan Marks Opening of New Kobe Headquarters
  July 17, 2018

• Taiho Exercises Option to Gain Asian Rights to Arcus’ I/O Candidate
  July 17, 2018

ページ

• « 先頭
• ‹ Prev
• …
• 378
• 379
• 380
• 381
• 382
• 383
• 384
• 385
• 386
• …
• Next ›
• 最終 »